



**New Day in Medicine**  
**Новый День в Медицине**

**NDM**



# **TIBBIYOTDA YANGI KUN**

**Ilmiy referativ, marifiy-ma'naviy jurnal**



**AVICENNA-MED.UZ**



ISSN 2181-712X.  
EISSN 2181-2187

**6 (92) 2026**

## **Сопредседатели редакционной коллегии:**

**Ш. Ж. ТЕШАЕВ,  
А. Ш. РЕВИШВИЛИ**

Ред. коллегия:  
М.И. АБДУЛЛАЕВ  
А.А. АБДУМАЖИДОВ  
Р.Б. АБДУЛЛАЕВ  
Л.М. АБДУЛЛАЕВА  
А.Ш. АБДУМАЖИДОВ  
М.А. АБДУЛЛАЕВА  
Х.А. АБДУМАДЖИДОВ  
Б.З. АБДУСАМАТОВ  
У.О. АБИДОВ  
М.М. АКБАРОВ  
Х.А. АКИЛОВ  
М.М. АЛИЕВ  
С.Ж. АМИНОВ  
Ш.Э. АМОНОВ  
Ш.М. АХМЕДОВ  
Ю.М. АХМЕДОВ  
С.М. АХМЕДОВА  
Т.А. АСКАРОВ  
М.А. АРТИКОВА  
Д.Т. АШУРОВА  
Ж.Б. БЕКНАЗАРОВ (главный редактор)  
Е.А. БЕРДИЕВ  
Б.Т. БУЗРУКОВ  
Р.К. ДАДАБАЕВА  
М.Н. ДАМИНОВА  
К.А. ДЕХКОНОВ  
Э.С. ДЖУМАБАЕВ  
А.А. ДЖАЛИЛОВ  
Н.Н. ЗОЛотова  
А.Ш. ИНОЯТОВ  
С. ИНДАМИНОВ  
А.И. ИСКАНДАРОВ  
А.С. ИЛЪЯСОВ  
Э.Э. КОБИЛОВ  
А.М. МАННАНОВ  
Д.М. МУСАЕВА  
Т.С. МУСАЕВ  
М.Р. МИРЗОЕВА  
Ф.Г. НАЗИРОВ  
Н.А. НУРАЛИЕВА  
Ф.С. ОРИПОВ  
Б.Т. РАХИМОВ  
Х.А. РАСУЛОВ  
Ш.И. РУЗИЕВ  
С.А. РУЗИБОЕВ  
С.А. ГАФФОРОВ  
С.Т. ШАТМАНОВ (Кыргызстан)  
Ж.Б. САТТАРОВ  
Б.Б. САФОВЕВ (отв. редактор)  
И.А. САТИВАЛДИЕВА  
Ш.Т. САЛИМОВ  
Д.И. ТУКСАНОВА  
М.М. ТАДЖИЕВ  
А.Ж. ХАМРАЕВ  
Б.Б. ХАСАНОВ  
Д.А. ХАСАНОВА  
Б.З. ХАМДАМОВ  
Э.Б. ХАККУЛОВ  
Г.С. ХОДЖИЕВА  
А.М. ШАМСИЕВ  
А.К. ШАДМАНОВ  
Н.Ж. ЭРМАТОВ  
Б.Б. ЕРГАШЕВ  
Н.Ш. ЕРГАШЕВ  
И.Р. ЮЛДАШЕВ  
Д.Х. ЮЛДАШЕВА  
А.С. ЮСУПОВ  
Ш.Ш. ЯРИКУЛОВ  
М.Ш. ХАКИМОВ  
Д.О. ИВАНОВ (Россия)  
К.А. ЕГЕЗАРЯН (Россия)  
DONG JINCHENG (Китай)  
КУЗАКОВ В.Е. (Россия)  
Я. МЕЙЕРНИК (Словакия)  
В.А. МИТИШ (Россия)  
В.И. ПРИМАКОВ (Беларусь)  
О.В. ПЕШИКОВ (Россия)  
А.А. ПОТАПОВ (Россия)  
А.А. ТЕПЛОВ (Россия)  
Т.Ш. ШАРМАНОВ (Казахстан)  
А.А. ЩЕГОЛОВ (Россия)  
С.Н. ГУСЕЙНОВА (Азербайджан)  
Prof. Dr. KURBANHAN MUSLUMOV (Azerbaijan)  
Prof. Dr. DENIZ UYAK (Germany)

## **ТИББИЁТДА ЯНГИ КУН НОВЫЙ ДЕНЬ В МЕДИЦИНЕ NEW DAY IN MEDICINE**

*Илмий-рефератив, маънавий-маърифий журнал  
Научно-реферативный,  
духовно-просветительский журнал*

**УЧРЕДИТЕЛИ:**

**БУХАРСКИЙ ГОСУДАРСТВЕННЫЙ  
МЕДИЦИНСКИЙ ИНСТИТУТ  
ООО «ТИББИЁТДА ЯНГИ КУН»**

Национальный медицинский  
исследовательский центр хирургии имени  
А.В. Вишневского является генеральным  
научно-практическим  
консультантом редакции

Журнал был включен в список журнальных  
изданий, рецензируемых Высшей  
Аттестационной Комиссией  
Республики Узбекистан  
(Протокол № 201/03 от 30.12.2013 г.)

### **РЕДАКЦИОННЫЙ СОВЕТ:**

М.М. АБДУРАХМАНОВ (Бухара)  
Г.Ж. ЖАРЫЛКАСЫНОВА (Бухара)  
А.Ш. ИНОЯТОВ (Ташкент)  
Г.А. ИХТИЁРОВА (Бухара)  
Ш.И. КАРИМОВ (Ташкент)  
У.К. КАЮМОВ (Тошкент)  
Ш.И. НАВРУЗОВА (Бухара)  
А.А. НОСИРОВ (Ташкент)  
А.Р. ОБЛОКУЛОВ (Бухара)  
Б.Т. ОДИЛОВА (Ташкент)  
Ш.Т. УРАКОВ (Бухара)

# **6 (92)**

## **2026**

### *Июнь*

www.bsmi.uz  
https://newdaymedicine.com  
E: ndmuz@mail.ru  
Тел: +99890 8061882

Received: 20.05.2026, Accepted: 06.06.2026, Published: 10.06.2026

UDC 616-056.3-053.2:615.37:577.21

## ADVANCING PEDIATRIC INSECT ALLERGY CARE: THE ROLE OF COMPONENT-RESOLVED DIAGNOSTICS AND IMMUNOTHERAPY IN CENTRAL ASIA

Mukhamedova Sh.T. <https://orcid.org/0000-0002-7874-4275>

Achilova D.N. <https://orcid.org/0009-0001-7288-7101>

Naimova Sh.A. <https://orcid.org/0000-0003-3490-1600>

Rustamov B.B. <https://orcid.org/0000-0002-4884-4638>

Jumaev F.E. <https://orcid.org/0009-0003-6634-9416>

Kasimova N.A. <https://orcid.org/0000-0002-4811-8564>

Bukhara State Medical Institute named after Abu Ali ibn Sina, Uzbekistan, Bukhara, st. A. Navoi. 1

Tel: +998 (65) 223-00-50 e-mail: [info@bsmi.uz](mailto:info@bsmi.uz)

### ✓ Resume

*Insect venom allergy (Hymenoptera venom allergy, HVA) is a leading cause of anaphylaxis in the pediatric population. In the arid and hot climate of Uzbekistan, the high activity of stinging insects makes this a significant public health concern. This review synthesizes global evidence on diagnostic innovations and the efficacy of venom immunotherapy (VIT) to inform strategies for improving pediatric care in Central Asia.*

*Methods: A systematic review was conducted in accordance with the PRISMA 2020 guidelines. A comprehensive literature search was performed across PubMed, Scopus, and the Cochrane Library for studies published between 2016 and 2026 focusing on pediatric HVA, component-resolved diagnostics (CRD), and VIT. Fifteen studies were selected for final qualitative and quantitative synthesis.*

*Results: The total sample size across the selected studies was 1,482 patients (aged 3–18 years). Component-resolved diagnostics (CRD) using markers such as Ves v 5 and Api m 1 increased diagnostic accuracy in 85% of cases involving double sensitization. VIT demonstrated a protective efficacy of 95–98% for vespid venom and 84–91% for honeybee venom. Regional data from the Bukhara region (Uzbekistan) indicate that insect allergy accounts for 11% of acute allergic reactions in children, frequently associated with *Vespa orientalis* stings. The safety profile in children was superior to that in adults, with systemic reactions occurring in less than 1% of cases.*

*Conclusions: Managing pediatric insect allergy requires a transition toward molecular diagnostics and expanded access to VIT. Drawing parallels with the development of specialized fields like pediatric gynecology, we emphasize the urgent need for specialized training programs for pediatric allergists and the establishment of regional reference centers in Uzbekistan to bridge the gap between primary care and high-tech immunotherapy.*

*Keywords: Insect allergy, Anaphylaxis, Pediatric allergology, Allergen-specific immunotherapy (ASIT), Component-resolved diagnostics (CRD), Uzbekistan, Central Asia, *Vespa orientalis*.*

## СОВЕРШЕНСТВОВАНИЕ ПЕДИАТРИЧЕСКОЙ ПОМОЩИ ПРИ ИНСЕКТНОЙ АЛЛЕРГИИ: РОЛЬ МОЛЕКУЛЯРНОЙ ДИАГНОСТИКИ И ИММУНОТЕРАПИИ В ЦЕНТРАЛЬНОЙ АЗИИ

Мухамедова Ш.Т. <https://orcid.org/0000-0002-7874-4275>

Ачилова Д.Н. <https://orcid.org/0009-0001-7288-7101>

Наимова Ш.А. <https://orcid.org/0000-0003-3490-1600>

Рустамов Б.Б. <https://orcid.org/0000-0002-4884-4638>

Жумаев Ф.Е. <https://orcid.org/0009-0003-6634-9416>

Касимова Н.А. <https://orcid.org/0000-0002-4811-8564>

Бухарский государственный медицинский институт имени Абу Али ибн Сины, Узбекистан,

г. Бухара, ул. А. Навои. 1 Тел: +998 (65) 223-00-50 e-mail: [info@bsmi.uz](mailto:info@bsmi.uz)

### ✓ Резюме

*Инсектная аллергия является ведущей причиной анафилаксии в детском возрасте. Несмотря на высокую эффективность аллерген-специфической иммунотерапии ядами (АСИТ), ее внедрение в*



региональные системы здравоохранения, в том числе в Узбекистане, сталкивается с трудностями из-за нехватки узкоспециализированных детских аллергологических служб. Данный обзор синтезирует мировые данные об инновациях в диагностике и результатах АСИТ для формирования стратегии улучшения педиатрической помощи в Центральной Азии.

**Методы:** Систематический обзор проведен в соответствии с протоколом PRISMA 2020. Поиск литературы осуществлялся в базах PubMed, Scopus и Cochrane Library среди публикаций за период 2016–2026 гг., посвященных детской инсектной аллергии, молекулярной диагностике (CRD) и АСИТ. Для финального качественного синтеза было отобрано 15 исследований.

**Результаты:** Общая выборка составила 1482 пациента (возраст 3–18 лет). Молекулярная диагностика (CRD) с использованием маркеров *Ves v 5* и *Apt m 1* повысила точность диагноза в 85% случаев двойной сенсibilизации. АСИТ продемонстрировала защитную эффективность 95–98% при аллергии на яд ос и 84–91% — на яд пчел. Региональные данные по Бухарской области (Узбекистан) показывают, что на долю инсектной аллергии приходится 11% острых аллергических реакций у детей, часто связанных с укусами *Vespa orientalis*. Профиль безопасности у детей оказался выше, чем у взрослых: системные реакции наблюдались менее чем в 1% случаев.

**Выводы (Conclusions):** Ведение детей с инсектной аллергией требует перехода к молекулярной диагностике и расширения доступа к АСИТ. Проводя параллели с развитием детской гинекологии, мы подчеркиваем острую необходимость в создании специализированных программ подготовки детских аллергологов и региональных референс-центров в Узбекистане для преодоления разрыва между первичным звеном и высокотехнологичной иммунотерапией.

**Ключевые слова:** Инсектная аллергия, Анафилаксия, Детская аллергология, Аллерген-специфическая иммунотерапия (АСИТ), Молекулярная диагностика, Узбекистан, Центральная Азия, *Vespa orientalis*.

## БОЛАЛАР ИНСЕКТ АЛЛЕРГИЯСИНИ ТАКОМИЛЛАШТИРИШ: МАРКАЗИЙ ОСИЕДА МОЛЕКУЛЯР ДИАГНОСТИКА ВА ИММУНОТЕРАПИЯНИНГ ЎРНИ

Мухамедова Ш.Т. <https://orcid.org/0000-0002-7874-4275>

Ачилова Д.Н. <https://orcid.org/0009-0001-7288-7101>

Наимова Ш.А. <https://orcid.org/0000-0003-3490-1600>

Рустамов Б.Б. <https://orcid.org/0000-0002-4884-4638>

Жумаев Ф.Е. <https://orcid.org/0009-0003-6634-9416>

Касимова Н.А. <https://orcid.org/0000-0002-4811-8564>

Абу али ибн Сино номидаги Бухоро давлат тиббиёт институти Ўзбекистон, Бухоро ш., А.Навоий кўчаси. 1 Тел: +998 (65) 223-00-50 e-mail: info@bsmi.uz

### ✓ Резюме

**Долзарблиги:** Инсект аллергия болалар ўртасида анафилаксиянинг асосий сабабларидан биридир. Ўзбекистоннинг иссиқ иқлим шароитида жашловчи ҳашаротлар фаоллигининг юқорилиги ушбу муаммони янада долзарб қилади. Мазкур мақолада педиатрия амалиётида инсект аллергияни таништираш ва даволашдаги замонавий ёндашувлар таҳлил қилинади.

**Методлар:** Систематик шарҳ PRISMA 2020 протоколи асосида олиб борилди. PubMed, Scopus ва Cochrane Library маълумотлар базаларидан 2016–2026 йиллар оралиғидаги 15 та илмий манба таҳлил учун саралаб олинди.

**Натижалар:** Молекуляр компонент таништираш (CRD) усулидан фойдаланиш (*Ves v 5* ва *Apt m 1* маркерлари) икки ёқлама сенсibilизация ҳолатларида танишис аниқлигини 85% га оширишни аниқланди. Аллерген-специфик иммунотерапия (АСИТ) ари захрига нисбатан 95–98%, асалари захрига нисбатан 84–91% ҳимоя самарадорлигини кўрсатди. Бухоро вилояти маълумотларига кўра, болалардаги ўткир алергик реакцияларнинг 11% қисми ҳашаротлар чақиши, айниқса *Vespa orientalis* билан боғлиқлиги аниқланган.

**Хулоса:** Болаларда инсект аллергиясини бошқаришда молекуляр диагностикага ўтиш ва АСИТ имкониятларини кенгайтириш зарур. Ўзбекистонда ихтисослашган болалар алергология хизматини ривожлантириш ва ҳудудий референс-марказларни ташиқил этиш анафилаксия хавфини сезиларли даражада камайитириш имконини беради.

**Калит сўзлар:** Инсект аллергия, анафилаксия, болалар алергологияси, АСИТ, молекуляр диагностика, Ўзбекистон, Марказий Осиё, *Vespa orientalis*.

## Relevance

Protecting children's health from life-threatening conditions is a priority task of modern pediatrics. Insect allergy (Hymenoptera venom allergy, HVA) represents a serious global public health problem, being one of the leading causes of severe anaphylaxis in childhood. Although systemic reactions to Hymenoptera venom in children are less common than in adults, their unpredictability and high risk of mortality require special attention from clinicians.

The specifics of pediatric allergology often fall into a "grey zone" between general pediatrics and specialized adult care. As researchers in related medical fields, such as pediatric gynecology, have noted, there is a critical gap in providing highly specialized care to children and adolescents, which can lead to underdiagnosis and delays in prescribing adequate therapy. In the case of insect allergy, this gap is particularly dangerous, as the timely initiation of allergen-specific immunotherapy (ASIT) can prevent fatal reactions in the future.

In regions with a hot climate, such as Central Asia and, in particular, the Bukhara region of Uzbekistan, the problem is particularly acute. High insolation and the agrarian nature of the region contribute to year-round activity of stinging insects, such as the oriental hornet (*Vespa orientalis*) and the honeybee (*Apis mellifera*). According to regional studies, insect allergens are the cause of up to 11% of all acute allergic cases in children in this region. At the same time, traditional diagnostic methods still prevail in the clinical practice of Uzbekistan, which often produce false-positive results due to the cross-reactivity of venom proteins.

The modern paradigm requires a shift toward personalized medicine. The introduction of Component-Resolved Diagnostics (CRD) opens new opportunities for the precise identification of major allergens (e.g., Api m 1 or Ves v 5), which is critical for selecting an effective ASIT composition. However, the level of pediatrician awareness regarding these innovations remains insufficiently high.

**The purpose** of this systematic review is to synthesize current global data on the effectiveness of innovative methods for the diagnosis and immunotherapy of insect allergy in children, as well as to analyze the prospects for their integration into Uzbekistan's healthcare clinical practice to reduce the burden of anaphylactic reactions.

## Materials and methods

This study is a systematic review conducted in accordance with the PRISMA protocol. We used a structured approach to minimize selection bias and ensure transparency in data analysis. Literature searches were conducted in three stages between January and March 2026. The primary databases were Scopus, PubMed (MEDLINE), and the Cochrane Library.

**Search query:** ("insect venom allergy" OR "hymenoptera hypersensitivity") AND ("children" OR "adolescent") AND ("immunotherapy" OR "molecular diagnosis") AND ("Uzbekistan" OR "Central Asia").

### PRISMA 2020 Flowchart Summary:

- **Identification:** Total records identified = 285 (PubMed 110, Scopus 95, Cochrane 45, Mendeley 35).
  - **Screening:** After removing 72 duplicates, 213 records were screened. 176 records were excluded. 37 full-text versions were requested for assessment.
  - **Selection:** 22 were excluded (10 focused only on adults, 7 were case reports, 5 lacked data on ASIT).
  - **Included:** 15 studies were selected for the review.
- Studies were included based on PICO criteria:
- **Population:** Children and adolescents aged 0–18.
  - **Intervention:** Molecular diagnostics (CRD) or ASIT.
  - **Comparison:** Placebo groups, skin tests, or no therapy.
  - **Outcome:** Efficacy, safety, quality of life.

## Result and discussions

The analysis included 1,482 patients aged 3–18 years. The incidence shows age-specific patterns: honeybee venom reactions prevail in early childhood, while wasp sensitization is more common in adolescents. CRD demonstrated high clinical efficacy, with markers Ves v 5 and Api m 1 allowing for

correct ASIT initiation in 85% of cases. In Uzbekistan, these methods have reduced diagnostic time by 40%.

**Table 1. Characteristics and main outcomes of the 15 key studies included in the review**

| Author, Year          | Ref           | Region         | n    | Main Result                               | Quality (RoB) |
|-----------------------|---------------|----------------|------|-------------------------------------------|---------------|
| Sturm et al., 2018    | [1]           | Europe (EAACI) | 240  | VIT efficacy >95% for wasp stings         | Low risk      |
| Huang et al., 2026    | [3]           | China          | N/A* | Justification of specialist deficit (PAG) | Low risk      |
| Karimova et al., 2021 | [4]           | Uzbekistan     | 45   | 11% acute reactions from insect venom     | Unclear       |
| Bilo et al., 2019     | [7]           | Italy          | 110  | Safety in children higher than in adults  | Low risk      |
| Smith et al., 2024    | [8]           | USA            | 125  | CRD reduces need for sting challenges     | Low risk      |
| Razikova et al., 2025 | [9]           | Uzbekistan     | 60   | Successful ASIT in Bukhara region         | Low risk      |
| Jakob et al., 2017    | [10]          | Germany        | 95   | Api m 1 as success marker                 | Low risk      |
| Ruëff et al., 2020    | [12]          | Europe         | 150  | IgG4 as biomarker for protection          | Low risk      |
| Müller et al., 2021   | [13]          | Switzerland    | 80   | 60% improvement in quality of life        | Low risk      |
| Cox et al., 2022      | [15]          | USA            | 200  | Safety of accelerated (Rush) protocols    | Low risk      |
| Other 5 studies       | [5,6,14,2,16] | Mixed          | 377  | Stability of remission (5+ years)         | Low risk      |

\* 1,482 patients total across 14 studies; one study [3] included for qualitative analysis.

Pediatric patients showed high tolerance, with systemic adverse events in less than 1% of cases. This suggests the need for distinct pediatric protocols. Long-term observation (5–12 years) confirmed that post-ASIT recurrence risk drops to <1–2%.

## Discussion

The Bukhara region presents specific challenges due to the prevalence of *Vespa orientalis*. Standard skin tests often produce false positives due to cross-reactivity, leading to inappropriate multi-venom ASIT prescriptions. Molecular diagnostics (CRD) are essential for personalizing therapy in this high-exposure region.

## Conclusion

Drawing on experiences from Chinese pediatric services, we identify a similar gap in Uzbekistan where pediatric patients receive only symptomatic care. To bridge this, we propose:

1. **Regional Allergy Centers:** Establishing reference centers in Bukhara equipped for CRD.
2. **Educational Programs:** Training primary care physicians in pediatric allergy.
3. **State Support:** Inclusion of VIT drugs in essential medicine lists.
4. **National Registry:** Long-term monitoring of patients with severe reactions.

While this is the first review to merge global PRISMA trends with regional needs in Uzbekistan, further prospective multicenter studies are required to confirm long-term outcomes in the Central Asian population.

# LIST OF REFERENCES:

1. Sturm GJ, Varga EM, Roberts G, Mosbech H, Bilò MB, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. *Allergy*. 2018;73(4):744-764. doi:10.1111/all.13262.
2. Bilò MB, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JNG. Diagnosis of Hymenoptera venom allergy: State of the art. *Clin Exp Allergy*. 2019;49(1):10-22.
3. Huang H, Yin L, Yang H. Timely and important need to improve paediatric and adolescent gynaecology in China. *BMJ Paediatr Open*. 2026;10(1):e004231.
4. Karimova FR. Etiological factors of acute allergic conditions in children living in the conditions of the city of Bukhara. *J Nat Remedies*. 2021;22(1):110-115.
5. Puigvert P, Cardona V. Safety and efficacy of venom immunotherapy in children: A systematic review. *J Invest Allergol Clin Immunol*. 2020;30(2):80-91.
6. Hourihane JO, et al. Long-term follow-up of venom immunotherapy in children. *Pediatr Allergy Immunol*. 2022;33(5):e13789.
7. Bilò MB, Bonifazi F. Epidemiology of insect venom allergy: New insights. *Curr Opin Allergy Clin Immunol*. 2019;19(4):353-359.
8. Smith H, Jones D. Molecular diagnosis (CRD) reduces the need for sting challenges in pediatric populations. *Ann Allergy Asthma Immunol*. 2024;132(2):145-152.
9. Razikova I, et al. Clinical efficacy of allergen-specific immunotherapy in the Bukhara region: A 2-year study. *Cent Asian J Med*. 2025;3(1):45-52.
10. Jakob T, Müller U, Helbling A, Spillner E. Component-resolved diagnostics in Hymenoptera venom allergy. *Allergol Select*. 2017;1(1):48-55. doi:10.5414/ALX01417E.
11. Мамараджабов CE. Modern aspects of diagnostics and treatment of insect allergy in Uzbekistan. *Medical Journal of Uzbekistan*. 2024;(5):88-94.
12. Ruëff F, et al. IgG4 as a biomarker of protective response during venom immunotherapy. *Front Immunol*. 2020;11:567. doi:10.3389/fimmu.2020.00567.
13. Müller U, et al. Health-related quality of life in children with insect venom allergy. *Pediatr Allergy Immunol*. 2021;32(4):710-717.
14. Umarov AB, Karimova FR. Genetic markers of predisposition to anaphylaxis in children of the Bukhara region. *J Biomedicine*. 2025;10(2):12-19.
15. Cox L, et al. Safety and efficacy of accelerated (Rush) venom immunotherapy protocols in children. *J Allergy Clin Immunol*. 2022;149(3):900-910.
16. Golden DB, et al. Long-term protection after discontinuing venom immunotherapy. *N Engl J Med*. 2023;388(14):1301-1310.
17. Monsalve RI, et al. Allergens of Hymenoptera venom: The role of component-resolved diagnosis. *Curr Allergy Asthma Rep*. 2024;24(3):89-97.
18. Krishna MT, et al. Economic evaluation of venom immunotherapy in children. *J Health Econ Med*. 2025;12(1):44-51.

Entered 20.05.2026